Browse Category

NYSE:ICE News 25 November 2025 - 28 November 2025

Is the US Stock Market Open Today? Black Friday Hours for Friday, November 28, 2025

Is the US Stock Market Open Today? Black Friday Hours for Friday, November 28, 2025

Yes, the US stock market is open today, Friday, November 28, 2025 — but it’s not a full trading day. The New York Stock Exchange (NYSE) and Nasdaq are running a shortened Black Friday session and will close early at 1:00 p.m. Eastern Time. Morningstar+4NYSE+4Nasdaq+4 US bond markets are also open, with trading scheduled to end at 2:00 p.m. Eastern Time. SIFMA+1 Below is a detailed look at today’s market hours, the latest news for November 28, 2025, and what this means for traders and investors. Quick Answer: Is the US Stock Market Open on November 28, 2025? Yesterday, Thursday, November 27, 2025 (Thanksgiving Day), both US stock
Is the U.S. Stock Market Open on Friday, November 28, 2025? Black Friday Trading Hours Explained

Is the U.S. Stock Market Open on Friday, November 28, 2025? Black Friday Trading Hours Explained

If you’re wondering “Is the U.S. stock market open this Friday, 28.11.2025?”, the short answer is: Yes, the U.S. stock market is open on Friday, November 28, 2025 — but it will close early at 1:00 p.m. Eastern Time. This special schedule applies to the major U.S. equity exchanges, including the New York Stock Exchange (NYSE) and the Nasdaq Stock Market, which officially designate Black Friday as an early‑close trading day rather than a full market holiday. Intercontinental Exchange+2Nasdaq+2 At the same time, U.S. bond markets will also operate on shortened hours, closing at 2:00 p.m. ET following industry recommendations from SIFMA (the Securities Industry and Financial Markets Association) and confirmed in multiple
26 November 2025
Wall Street Mourns NYSE Executive Cassandra Seier After Reported Bahamas Cycling Accident

Wall Street Mourns NYSE Executive Cassandra Seier After Reported Bahamas Cycling Accident

The global financial community is grieving the sudden death of Cassandra Seier, the New York Stock Exchange’s head of international capital markets and a leading advocate for women in finance. As tributes pour in from New York to Singapore, colleagues are remembering her not just as a powerhouse dealmaker, but as a mentor and builder of opportunity across Wall Street. Reuters+1 Shock on Wall Street as NYSE Confirms Her Death NYSE officials confirmed on Monday that Cassandra Seier died over the weekend, in news first reported by Reuters and quickly echoed across financial media. The exchange did not disclose a
25 November 2025

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop